As previously mentioned, two GLP-1 RAs are available for the management of weight even in patients who do not have diabetes [33, 34]
Research aims to determine whether GLP-3 causes similar GI side effects as GLP-1, if tolerability differs between the peptides, what optimal dosing strategies minimize side effects, and if GLP-3 might suit patients who dont tolerate GLP-1 agonists well
While its not yet officially approved for human consumption, the studies conducted have uncovered multiple benefits, making Ipamorelin an exciting peptide that may eventually contribute to the health and wellness of individuals
Some medications, like GLP-1 drugs for obesity, are also peptides
In head-to-head trials, tirzepatide produced greater reductions in the measured endpoints: superior HbA1c and weight loss in SURPASS-2, and a 20.2% versus 13.7% body-weight reduction in SURMOUNT-5
Finally, at the health system level, sustained support through health coaching, remote monitoring, and defined interdisciplinary roles fosters continuity and structured follow-up